Stockreport

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus Holdings, Inc.  (LNTH) 
Last lantheus holdings, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.lantheus.com/investor-relations
PDF Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI s [Read more]